Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyeChild 01: Phase III Trial in Children With Acute Myeloid Leukaemia
NCT02724163Phase 3Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Apr 2016
- Primary completion
- Dec 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (7 arms), sponsored by University of Birmingham. Primary endpoints: Incidence of dose limiting toxicities at day 45, Event Free Survival up to 16 years and 2 more. Started Apr 2016; status: active, not recruiting.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02724163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724163.